Unternehmensübersicht
Omada Health, Inc. operates within the healthcare sector, specifically serving the health information services industry by delivering virtual care programs across the United States. The firm focuses on managing cardiometabolic conditions such as prediabetes, diabetes, and hypertension, alongside offering physical therapy for musculoskeletal issues and support programs for members utilizing glucagon-like peptides. This operational scale is reflected in a market capitalization of $698.56M and an annual revenue of $260.21M for the trailing twelve months. With an employee base of 916, the company maintains a significant presence in the digital health landscape, where its market cap indicates a valuation that reflects investor expectations for growth in the virtual care space despite current profitability challenges. The revenue figure of $260.21M suggests a substantial operational footprint, positioning the company as a notable player in the expanding market for remote patient monitoring and chronic disease management solutions.
Finanzielle Gesundheit
The company reported a revenue of $260.21M over the trailing twelve months, yet it posted a net income of $-12,778,000 and an EBITDA of $-6,481,000. The substantial gap between the positive revenue and the negative net income reveals a cost structure where operating expenses significantly exceed gross profits, resulting in a loss before interest and taxes. Despite the net loss, the entity generated free cash flow of $15.34M, which provides a degree of financial flexibility to fund operations and potentially invest in technology or expansion without immediate reliance on external equity financing. The gross margin stands at 65.7%, indicating efficient product pricing and cost of goods sold relative to revenue, while the operating margin of 4.3% and profit margin of -4.9% highlight the pressure from overhead costs and the current inability to convert operations into a net profit. The company holds $222.32M in cash and has no listed debt, creating a conservative balance sheet structure that relies on equity rather than leverage. The current ratio is 3.60, which indicates a robust short-term liquidity position where current assets are more than three times the value of current liabilities. Return on Equity is -8.7% and Return on Assets is -3.3%, metrics that reveal that management has not yet achieved profitability, resulting in negative returns on the capital base deployed to generate the company's revenue.
Bewertungsanalyse
The valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of 33.21, implying that the market prices in significant future earnings growth to justify current valuation levels. The price-to-book ratio is 3.02, suggesting that the market values the company at a significant premium over its tangible book value, likely reflecting intangible assets like proprietary software and brand equity. Alternative valuation measures include a price-to-sales ratio of 2.68 and an EV/EBITDA of -73.48, which further underscore the disconnect between current cash flows and market price due to the negative EBITDA. The stock has traded between a 52-week low of $10.28 and a 52-week high of $28.40, indicating a wide trading range that captures significant volatility in investor sentiment regarding the company's turnaround potential. While the beta is N/A, the wide spread between the 52-week high and low suggests that the stock price is highly sensitive to market conditions and company-specific developments related to its virtual care programs. The forward P/E multiple of 33.21 is notably higher than the price-to-sales ratio, indicating that investors are willing to pay a high multiple for future earnings that are currently unproven given the negative net income.
Growth & Income
Revenue growth accelerated to 58.1% year-over-year, demonstrating a rapid expansion in the top line, whereas earnings growth is N/A due to the company's continued losses. Because earnings are negative, they are not growing faster than revenue, and the focus remains on scaling revenue to eventually cover the high operating costs inherent in the health information services industry. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available cash flow back into the business rather than distributing returns to shareholders. The overall growth and income profile is characterized by aggressive revenue expansion funded by existing cash reserves, with no current reliance on dividend income for investors. This strategy prioritizes market share acquisition and program development over immediate profitability, a common approach in the growth phase of the healthcare technology sector. The 58.1% revenue growth rate is a critical metric that supports the high forward P/E multiple, as it signals potential for future earnings materialization once cost structures are optimized.